BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29

• Press Releases

  Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

  August 7, 2025

   · 

  15 min read
• Press Releases

  Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates

  August 7, 2025

   · 

  1 min read
• Press Releases

  Palleon Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of E-602 (HLX79), a Potential First-In-Class Treatment for Active Glomerulonephritis

  August 7, 2025

   · 

  3 min read
• Press Releases

  Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance

  August 7, 2025

   · 

  16 min read
• Press Releases

  Cell and Gene Therapy Clinical Trials Market Size Expected to Hit USD 54.29 Bn by 2034

  August 7, 2025

   · 

  1 min read
• Press Releases

  Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

  August 7, 2025

   · 

  8 min read
• 

  Earnings

  Despite Safety Drama, Sarepta Beats Q2 Estimates—But No Thanks to Elevidys Sales

  Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.

  August 7, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Stem Cell Therapy Market Size to Hit USD 78.39 Billion by 2032, Growing at a CAGR of 22.8% from 2025 to 2032 | Coherent Market Insights

  August 7, 2025

   · 

  1 min read
• 

  Obesity

  UPDATE: Lilly’s Oral Weight Loss Drug Underdelivers, But Executives See Real World Opportunity

  Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ bear scenario for the oral med. Executives brushed off the concerns and said the drug will still have a wide advantage on the market.

  August 7, 2025

   · 

  4 min read

   · 

  Annalee Armstrong
• 

  Mergers & acquisitions

  Novartis Continues Hunt for New Assets With Rumored Takeover of RNA Specialist Avidity

  There is no certainty that the buyout will come to pass, according to The Financial Times, which first reported the rumors.

  August 7, 2025

   · 

  2 min read

   · 

  Tristan Manalac